Phytochemicals As Lead Compounds for New Drug Discovery
Phytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the development of new drugs and chemical entities. Functional bioactive compounds of plant origin have been an invaluable s...
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Language: | English |
| Published: |
San Diego :
Elsevier,
2019.
|
| Subjects: | |
| Online Access: | ScienceDirect |
Table of Contents:
- Front Cover; Phytochemicals as Lead Compounds for New Drug Discovery; Phytochemicals as Lead Compounds for New Drug Discovery; Copyright; Contents; List of contributors; I
- Plants as natural sources of drugs; 1
- Plant secondary metabolites as lead compounds for the production of potent drugs; 1.1 Medicinal plants and phytochemicals; 1.1.1 Case Study 1: development of new analogues of combretastatins as tubulin inhibitors; 1.1.2 Case Study 2: development of coumarin analogues as antiretroviral agents; 1.1.3 Case Study 3: oseltamivir phosphate as an antiinfluenza drug; 1.2 Conclusion
- 3.1.3 Reverse pharmacology3.1.4 Computer-aided drug discovery process; 3.1.4.1 Target identification; 3.1.4.1.1 Genomic techniques; 3.1.4.1.2 Forward and reverse genetics; 3.1.4.1.3 Proteomics; 3.1.4.2 Target validation; 3.1.4.3 Lead identification; 3.1.4.4 Lead optimization; 3.1.5 Structural considerations in drug discovery; 3.1.5.1 Affinity profiling; 3.1.5.2 Target specificity; 3.1.5.3 Quantitative structure-activity relationships; 3.1.5.3.1 1D-QSAR; 3.1.5.3.2 2D-QSAR; 3.1.5.3.3 3D-QSAR; 3.1.5.3.4 Multidimensional quantitative structure-activity relationship; 3.1.5.4 Molecular docking
- 3.1.6 Bioinformatics and genomics3.1.6.1 Bioinformatics-overview; 3.1.6.2 Bioinformatics tools; 3.1.6.3 Writing language for software packages; 3.1.7 Implications of the human genome project on in silico drug discovery; 3.1.8 Current in silico analyses possible; 3.1.9 ADME-Tox; 3.1.10 Future possibilities; References; 4
- FDA drug candidacy acceptance criteria and steps: problems and way forward; 4.1 Introduction; 4.1.1 Drug approval framework; 4.1.1.1 The clinical trials; 4.1.2 FDA acceptance of foreign clinical studies not conducted under an IND
- 4.1.2.1 Acceptance of foreign clinical studies4.1.3 Regulatory approaches on botanical drug development (NDAs); 4.1.3.1 Challenges in developing global botanical drugs; 4.1.3.2 Development of novel botanical drugs using traditional medicinal plant sources; 4.1.3.3 Description and documentation of products; 4.1.3.4 Quality control; 4.1.3.4.1 Quality control systems; 4.1.3.4.2 Record and document control; 4.1.3.5 Botanical raw materials; 4.1.3.6 Safety tests on animals; 4.1.3.7 Placebo; 4.1.3.8 Labeling; 4.1.3.9 Nonclinical safety assessment; 4.1.3.9.1 Pharmacokinetic studies